Essight Biopharma

Esight Biopharma is a clinical-stage biotechnology company based in Shanghai, China, focused on developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. The company utilizes a proprietary platform to isolate, expand, and enhance TILs, aiming to overcome the challenges of the tumor microenvironment. Its lead program, GT101, is an autologous TIL therapy currently in Phase 1/2 clinical trials for indications such as cervical cancer and melanoma. Esight is also advancing a pipeline of next-generation, genetically modified TIL therapies designed for improved efficacy and broader application across various solid malignancies. The company has secured significant venture capital funding to support its clinical development and manufacturing infrastructure.